Pharmacological profile of a novel, non-TZD PPARγ agonist

Diabetes, Obesity and Metabolism

Volumn 7, Issue 5, 2005, Pages 536-546

  Chen, Xiaoli ^a   Osborne, M C ^a   Rybczynski, P J ^a   Zeck, R ^a   Yang, M ^a   Xu, J ^a   Zhou, L ^a   Cryan, E ^a   Tang, Y ^a   Demarest, K T ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antidiabetic drugs; Glycaemic control; Haematocrit; HbA1c; OGTT; PPAR

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; GLUCOSE; HEMOGLOBIN A1C; HYDROXYPROPYLMETHYLCELLULOSE; INSULIN; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; RWJ 348260; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; BINDING ASSAY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DYSLIPIDEMIA; FEMALE; GENE INDUCTION; GENE TARGETING; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; LIVER CELL; LIVER WEIGHT; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; PROADIPOCYTE; RAT; RAT STRAIN; RECEPTOR BINDING; UPREGULATION; WHITE ADIPOSE TISSUE;

EID: 23844470219     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00425.x     Document Type: Article

References (40)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-650.
2. Chen F, Law SW, O'Malley BW. Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. Biochem Biophys Res Commun 1993; 196: 671-677.
3. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem 1993; 268: 26817-26820.
4. Kliewer SA, Forman BM, Blumberg B et al. Differential expression and activation of a family of murine peroxisome proliferator activated receptors. Proc Natl Acad Sci USA 1994; 91: 7355-7359.
5. Staels B, Auwerx J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr Pharm Design 1997; 3: 1-14.
6. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARg2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224-1234.
7. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARg2, a lipid-activated transcription factor. Cell 1994; 79: 1147-1156.
8. Lehman JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma. J Biol Chem 1995; 270: 12953-12956.
9. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995; 83: 803-812.
10. 2 metabolite binds peroxisome, proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995; 83: 813-819.
11. Grossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Expert Opin Investig Drugs 1997; 6: 1025-1040.
12. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1997; 45: 1661-1669.
13. Willson TM, Cobb JE, Cowan DJ et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-668.
14. Oakes ND, Thalen PG, Jacinto SM, Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 2001; 50: 1158-1165.
15. Fruebis J, Tsao, TS, Javorschi S et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-2010.
16. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp3o enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
17. Combs TP, Wagner JA, Berger J et al. Induction of adipocyte omplement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007.
18. Hofmann C, Lorenz K, Braithwaite SS et al. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134: 264-270.
19. Miles PD, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM. TNF-alpha induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997; 46: 1678-1683.
20. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
21. Berger J, Tanen M, Elbrecht A et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001; 276: 12629-12635.
22. Rybczynski PJ, Zeck R, Dudash J et al. Benzoxazinones as PPARγ agonists. 2. sar of the amide substituent and in vivo results in a type 2 diabetes model. J Med Chem 2004; 47: 196-209.
23. Netoglitazone. Sorbera LA, Castaner J, Del Fresno M, Silvestre J. Drugs Future 2002; 27: 132-139.
24. Burris TP, Pelton PD, Zhou L, Osborne MC, Cryan E, Demarest KT. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. Mol Endocrinol 1999; 13: 410-417.
25. Liang Y, Chen X, Osborne M, DeCarlo S, Jetton T, Demarest K. Topiramate Ameliorates Hyperglycemia and Improves Glucose-stimulated Insulin Release in ZDF Rats and db/db Mice. Diabetes Obes Metab 2004.
26. Berger JP, Petro AE, Macnaul KL et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol Endocrinol 2003; 17: 662-676.
27. Tang Y, Zhou L. Characterization of adenosine A1 receptors in human proximal tubule epithelial (HK-2) cells. Receptors Channels 2003; 9: 67-75.
28. Young PW, Buckle DR, Cantello BCC et al. Identification of high affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferatior-activated receptor γ. J Pharmacol Exp Ther 1998; 284: 751-759.
29. Reginato MJ, Bailey ST, Krakow SL et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 1998; 273: 32679-32684.
30. Hollenberg HK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. 2003; 115 (8A): 111S-115S.
31. Boelsterli UA, Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem Pharmacol 2002; 63: 1-10.
32. Gavrilova O, Haluzik M, Matsusue K et al. Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body mass. J Biol Chem 2003; 278: 34268-34276.
33. Hockings PD, Changani KK, Saeed N et al. Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats. Diabetes Obes Metab 2003; 5: 234-243.
34. Freedman R, Uwaifo G, Lutchman G et al. Changes in insulin sensitivity and improvements in liver histology in patients with nonalcoholic steatohepatitis (NASH) treated with pioglitazone (PIO). Diabetes 2003; 52 (Suppl. 1): A76 [Abstract 324-OR].
35. Norris AW, Chen L, Fisher SJ et al. Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003; 112: 608-618.
36. Heverner AL, He W, Barak Y et al. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 2003; 9: 1491-1497.
37. Way JM, Harrington WW, Brown KK et al. Comprehensive messenger ribonucleic acid proofing reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinol 2001; 142: 1269-1277.
38. Guan H, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002; 8: 1122-1128.
39. Martin G, Schoonjans K, Lefebvre A-M, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 1977; 272: 28210-28217.
40. Roden M, Stingl H, Chandramouli V et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 2000; 49: 701-707.